Immunome : Corporate Presentation

Harnessing the Power

of the Human Memory

B Cell

JANUARY 2023

Immunome, Inc.

665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | immunome.com

Copyright © 2023 Immunome, Inc. All rights reserved.

Disclaimers and Forward-Looking Statements

Copyright © 2023 Immunome, Inc. All rights reserved.

2

This presentation includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities

Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding our beliefs and expectations regarding the advancement of our oncology and infectious disease programs and platform, execution of our regulatory, clinical and strategic plans, therapeutic potential and benefits of our programs and anticipated upcoming milestones for our programs, as well as the timing and progress of each of the foregoing matters. Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "suggest," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the following: our ability to execute on our strategy, including with respect to R&D efforts, IND submissions and other regulatory filings, timing of these filings and the timing and nature of governmental authority feedback regarding the same, initiation and completion of any clinical studies, confirmatory testing and other anticipated milestones as and when anticipated; the fact that research and development data are subject to differing interpretations and assessments, including during the peer review/publication process in the scientific community and by regulatory authorities; whether our data will be published in a scientific journal and, if so, when and with what modifications; the effectiveness of our product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with earlier-published data and/or data used for advancing the product candidates; the fact that changes in the profile of the diseases that our programs target could emerge that could impact our ability to address those changes; our ability to fund operations; our reliance on vendors; our ability to execute on our plans for collaborations and partnerships; the competitive landscape; the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated milestones; and the additional risks and

uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual

Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 28, 2022, and elsewhere in Immunome's Quarterly Reports on form 10-Q and other filings and reports with the SEC.

All statements contained in this presentation are made as of the date specified on the cover, and we undertake no duty to publicly update or revise any such statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

This presentation may contain product names, trade names, trademarks and service marks of Immunome and of other organizations, which are the properties of their respective owners.

Statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of

this presentation, including independent market research, industry publications and surveys, governmental agency publications and other publicly available information. While we believe that information provides a reasonable basis for these statements, it may be limited or incomplete and we may have not independently verified it. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review or verification of, all relevant information.

We make statements and predictions about future dates for achievement of milestones related to our platform and our programs in this presentation. These statements and predictions involve risks and uncertainties based on various factors and evolution over time and, therefore, actual dates for these milestones may differ.

In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind.

Immunome: Three-Pronged Strategy

Powered by Human Memory B Cell Interrogation

01	02	03
Successfully execute on AbbVie	Extract value from the breadth of	Advance proprietary oncology
collaboration	Immunome's Discovery Engine	pipeline

Copyright © 2023 Immunome, Inc. All rights reserved.

3

• $30M upfront
• Eligible for up to:
• • $70M platform access payments
  • Per target option payments (low single digit millions)
  • $2.7B downstream economics
  • Tiered royalties

→ Platform and asset-based	→ IMM-ONC-01 (targeting IL-38)
partnerships	IND submission by mid-2023
→ Novel oncology target/antibody	→ Research pipeline
pairs

• Includes ADC, TCE modalities

Cash runway at least through 3Q 2024

Strategic Discovery Collaboration with AbbVie

Immunome's approach has the potential to unlock novel cancer biology and yield multiple therapeutic candidates.

STEVE DAVIDSEN

VP, Oncology Discovery Research, AbbVie

Copyright © 2023 Immunome, Inc. All rights reserved.

4

This collaboration with AbbVie, a true leader in the development and commercialization of oncology therapeutics, demonstrates the strength of Immunome's Discovery Engine.

PURNANAND SARMA

President & CEO, Immunome

• AbbVie option to purchase worldwide rights for up to 10 novel target-antibodypairsarising from threespecified tumor types
• Key Financial Terms
• • $30M upfront payment
  • Eligible for additional payments up to:
  • • $70M platform access payments (in addition to potential per target option payments - low single digit millions)
    • $120M per target development and first commercial sale milestones
    • $150M per target further sales-based milestones
    • Tiered royalties on global sales

We See the Disease Through the Lens of a Memory B Cell

Interrogate Most Educated Components of Immune Response in an Unbiased Manner at Industrial Scale

Patient responses unveil novel disease targets

Copyright © 2023 Immunome, Inc. All rights reserved.

01

Patients' immune responses recognize and respond to disease in clinically important ways1

Cataloging the Context-Dependent B Cell Response Against Cancer

02	03
Proprietary Discovery	Patient Ab responses
Engine interrogates	point to actionable
function of patient	public targets2
memory B cell responses
We See the Disease Through the	Broad Applicability Across
Lens of a Memory B Cell	Therapeutic Areas

Immune
Modulation
Novel
Targets	Discovery
Extracellular	Engine
Matrix

5

1. Nature 577:549-555,556-560, & 561-65 (2020)
2. Immunome internal data